We are live on ! Find out more
XENE icon

Xenon Pharmaceuticals
XENE

63 hedge funds and large institutions have $180M invested in Xenon Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

64% more capital invested

Capital invested by funds: $110M → $180M (+$70.1M)

44% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 16

9% more funds holding

Funds holding: 58 → 63 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.26% less ownership

Funds ownership: 69.15% → 68.88% (-0.26%)

Holders
63
Holders Change
+5
Holders Change %
+8.62%
% of All Funds
1.36%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
8
Increased
23
Reduced
16
Closed
3
Calls
$10K
Puts
–
Net Calls
+$10K
Net Calls Change
+$4K

Top Buyers

1
EAM
Eventide Asset Management
Massachusetts
+$1.66M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.06M
3
Capital International Investors
Capital International Investors
California
+$1M
4
GIM
Granahan Investment Management
Massachusetts
+$921K
5
SCM
Stonepine Capital Management
Oregon
+$838K

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$1.58M
2
Two Sigma Investments
Two Sigma Investments
New York
-$1.2M
3
Millennium Management
Millennium Management
New York
-$823K
4
JP Morgan Chase
JP Morgan Chase
New York
-$792K
5
Renaissance Technologies
Renaissance Technologies
New York
-$792K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACA
1
Avoro Capital Advisors
New York
$24.4M – – –
BI
2
BVF Inc
California
$18.2M – – –
VC
3
Vivo Capital
California
$14.3M – – –
Adage Capital Partners
4
Adage Capital Partners
Massachusetts
$13.2M – – –
Capital International Investors
5
Capital International Investors
California
$10.7M +$1M +118,326 +13%
Capital World Investors
6
Capital World Investors
California
$9.79M – – –
ACM
7
Aquilo Capital Management
California
$9.67M – – –
Point72 Asset Management
8
Point72 Asset Management
Connecticut
$8.64M +$1.06M +125,000 +17%
Citadel Advisors
9
Citadel Advisors
Florida
$6.63M -$1.58M -186,279 -22%
O
10
OrbiMed
New York
$6.45M – – –
EAM
11
Eventide Asset Management
Massachusetts
$6.31M +$1.66M +196,258 +46%
ACP
12
Acuta Capital Partners
California
$5.61M +$127K +15,000 +3%
SFM
13
Sphera Funds Management
Israel
$5.42M +$714K +84,171 +19%
SSA
14
Schonfeld Strategic Advisors
New York
$5.08M +$84.3K +9,942 +2%
Renaissance Technologies
15
Renaissance Technologies
New York
$4.8M -$792K -93,400 -17%
DCM
16
DAFNA Capital Management
California
$3.36M +$788K +92,984 +39%
GPCM
17
Granite Point Capital Management
Massachusetts
$3.08M +$424K +50,000 +20%
BlackRock
18
BlackRock
New York
$2.72M -$137K -16,131 -6%
EP
19
Eversept Partners
New York
$2.28M +$163K +19,236 +9%
DMK
20
David M. Knott
$1.82M +$50.9K +6,000 +3%
AGA
21
Altrinsic Global Advisors
Connecticut
$1.63M +$84.8K +10,000 +7%
State of New Jersey Common Pension Fund D
22
State of New Jersey Common Pension Fund D
New Jersey
$1.58M – – –
AS
23
Altshuler Shaham
Israel
$1.46M +$387K +45,600 +47%
GIM
24
Granahan Investment Management
Massachusetts
$1.1M +$921K +108,679 New
SCM
25
Stonepine Capital Management
Oregon
$1M +$838K +98,860 New
1
2 3

XENE Hedge Fund Activity: Q1 2019 in Review

63 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2019, worth a combined $180M — up 64% from $110M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new XENE positions and 3 closed out — a net gain of 5 holders — while 23 added to existing stakes and 16 trimmed.

The largest buyer was Eventide Asset Management, adding an estimated $1.66M. The largest seller was Citadel Advisors, cutting an estimated $1.58M.

  • 63 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2019, up from 58 in Q4 2018.
  • Funds reported $180M of Xenon Pharmaceuticals stock for Q1 2019, up 64% quarter-over-quarter.
  • 8 funds opened new Xenon Pharmaceuticals positions in Q1 2019 and 3 closed out, a net change of +5 holders.
  • The largest Xenon Pharmaceuticals buyer in Q1 2019 was Eventide Asset Management, an estimated $1.66M added.
  • The largest Xenon Pharmaceuticals seller in Q1 2019 was Citadel Advisors, an estimated $1.58M sold.

Based on aggregated 13F filings for Q1 2019.